Phase II study of iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumors; the need for alternative strategies in the investigation of new agents in GCT
- 1 November 1992
- journal article
- clinical trial
- Published by Springer Nature in Investigational New Drugs
- Vol. 10 (4) , 327-330
- https://doi.org/10.1007/bf00944190
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Justification for Evaluating New Anticancer Drugs in Selected Untreated Patients With Extensive-Stage Small-Cell Lung Cancer: An Eastern Cooperative Oncology Group Randomized StudyJNCI Journal of the National Cancer Institute, 1992
- Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast CancerJNCI Journal of the National Cancer Institute, 1991
- Salvage chemotherapy for patients with germ cell tumors. The memorial sloan-kettering cancer center experience (1979–1989)Cancer, 1991
- The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumorsCancer, 1990
- PHASE-II TRIAL OF CARBOPLATIN IN PATIENTS WITH ADVANCED GERM-CELL TUMORS REFRACTORY TO CISPLATIN1987
- Teniposide (VM-26), an overlooked highly active agent in small-cell lung cancer. Results of a phase II trial in untreated patients.Journal of Clinical Oncology, 1986
- Phase II study of teniposide in small cell carcinoma of the lung.1984
- Clinical safety and tolerance of mitoxantrone (Novantrone)Cancer Treatment Reviews, 1983
- PHASE-I CLINICAL-TRIAL OF CIS-DICHLORO-TRANS-DIHYDROXY-BIS-ISOPROPYLAMINE PLATINUM(IV) (CHIP)1983
- Reporting results of cancer treatmentCancer, 1981